83_FR_30574 83 FR 30449 - Office of the Secretary; Amended Notice of Meeting

83 FR 30449 - Office of the Secretary; Amended Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 125 (June 28, 2018)

Page Range30449-30449
FR Document2018-13895

Federal Register, Volume 83 Issue 125 (Thursday, June 28, 2018) 
[Federal Register Volume 83, Number 125 (Thursday, June 28, 2018)]
[Notices]
[Page 30449]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-13895]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Secretary; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the 
Interagency Pain Research Coordinating Committee, July 09, 2018, 02:00 
p.m. to July 09, 2018, 04:00 p.m., National Institutes of Health, 
Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD, 20892 
which was published in the Federal Register on May 18, 2018, 83 FR 
23283.
    The meeting notice is amended to change the time of the meeting 
from 2-4 p.m. to 4-6 p.m. Date has not changed. The meeting is open to 
the public.

    Dated: June 22, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13895 Filed 6-27-18; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 125 / Thursday, June 28, 2018 / Notices 30449 Intellectual Property Cancer Institute receives written for Disease Control and Prevention; United States Provisional Patent evidence and argument that establishes Department of Health and Human Application No. 61/040,005, filed March that the grant of the license would not Services. 27, 2008 and entitled ‘‘Human be consistent with the requirements of ACTION: Notice of meetings. Monoclonal Antibodies Specific for 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public SUMMARY: Notice is hereby given of the Mesothelin’’ [HHS Reference No. may file comments or objections. meetings on July 22–23, 2018, of the E–079–2008/0–US–01]; Comments and objections, other than Substance Abuse and Mental Health PCT Patent Application PCT/US2009/ those in the form of a license Services Administration’s (SAMHSA) 038228, filed March 25, 2009 and application, will not be treated Tribal Technical Advisory Committee entitled ‘‘Human Monoclonal Antibody confidentially, and may be made (TTAC); on July 23 and July 25, 2018, Against Mesothelin’’ [HHS Reference publicly available. of the Centers for Disease Control and No. E–079–2008/0–PCT–02]; and US License applications submitted in Prevention (CDC)/Agency for Toxic Patent No. 8,357,783, filed September response to this Notice will be Substances and Disease Registry 22, 2010, Issued January 22, 2013 and presumed to contain business (ATSDR) Tribal Advisory Committee entitled ‘‘Human Anti-Mesothelin confidential information and any release (TAC); and on July 24, 2018, of the Joint Monoclonal Antibodies’’ [HHS of information in these license Tribal Advisory Committee (JTAC). Reference No. E–079–2008/0–US–06]. The patent rights in these inventions applications will be made only as DATES: have been assigned and/or exclusively required and upon a request under the SAMHSA TTAC licensed to the government of the Freedom of Information Act, 5 U.S.C. July 22, 2018, 1:00 p.m. to 5:00 p.m. United States of America. 552. EDT (OPEN) The prospective exclusive license Dated: June 21, 2018 July 23, 2018, 9:00 a.m. to 5:00 p.m. territory may be worldwide and the Richard U. Rodriguez, EDT (OPEN) field of use may be limited to: ‘‘The • CDC/ATSDR TAC Associate Director, Technology Transfer development of a mesothelin chimeric July 23, 2018, 8:00 a.m. to 6:00 p.m. Center, National Cancer Institute. antigen receptor (CAR)-based EDT (OPEN) [FR Doc. 2018–13893 Filed 6–27–18; 8:45 am] immunotherapy using autologous or July 25, 2018, 8:00 a.m. to 12:00 p.m. BILLING CODE 4140–01–P EDT (OPEN) allogeneic T cells either transduced • JTAC with a retroviral vector (including July 24, 2018, 1:00 p.m. to 5:00 p.m. lentiviral vectors) or modified using a DEPARTMENT OF HEALTH AND EDT, (OPEN) gene-editing technology, wherein the HUMAN SERVICES vector expresses a CAR comprising: ADDRESSES: (1) Single antigen specificity for National Institutes of Health • SAMHSA TTAC binding to mesothelin, and Marriott Wardman Park Hotel, 2660 (2) at least (a) the complementary Office of the Secretary; Amended Woodley Road NW, Washington, determining region (CDR) sequences of Notice of Meeting DC 20008 the anti-mesothelin antibody known as • CDC/ATSDR TAC Notice is hereby given of a change in HHS Headquarters, Hubert H. m912, and (b) a T cell signaling domain; the meeting of the Interagency Pain for the prophylaxis and treatment of Humphrey Building, 200 Research Coordinating Committee, July Independence Avenue SW, mesothelin-expressing human cancers.’’ 09, 2018, 02:00 p.m. to July 09, 2018, This technology discloses a Washington, DC 20201 04:00 p.m., National Institutes of Health, • JTAC monoclonal antibody and methods of Building 31, 31 Center Drive, using the antibody for the treatment of HHS Headquarters, Hubert H. Conference Room 6, Bethesda, MD, Humphrey Building, 200 mesothelin-expressing cancers, 20892 which was published in the including mesothelioma, lung cancer, Independence Avenue SW, Federal Register on May 18, 2018, 83 Washington, DC 20201. stomach/gastric cancer, ovarian cancer, FR 23283. and pancreatic cancer. The specific FOR FURTHER INFORMATION CONTACT: The meeting notice is amended to antibody covered by this technology is TTAC and JTAC, Mirtha Beadle, MPA, change the time of the meeting from 2– designated as m912, which is a fully Director, Office of Tribal Affairs and 4 p.m. to 4–6 p.m. Date has not changed. human monoclonal antibody against Policy, Substance Abuse and Mental The meeting is open to the public. mesothelin. Health Services Administration, 5600 Mesothelin is a cell surface antigen Dated: June 22, 2018. Fishers Lane, Rockville, Maryland that is preferentially expressed on Sylvia L. Neal, 20857, Telephone: (240) 276–0641, certain types of cancer. The m912 Program Analyst, Office of Federal Advisory Email: otap@samhsa.hhs.gov. antibody selectively binds to the Committee Policy. CDC/ATSDR/TAC, Carmen Clelland, mesothelin on the surface of cancer cells [FR Doc. 2018–13895 Filed 6–27–18; 8:45 am] PharmD, MPA, MPH, Associate and induces cell death of those cancer BILLING CODE 4140–01–P Director for Tribal Support, Office for cells while leaving healthy cells State, Tribal, Local and Territorial unharmed. This selectivity may lead to Support, Centers for Disease Control fewer side effects due to decreased non- DEPARTMENT OF HEALTH AND and Prevention, 4770 Buford specific killing of cells. HUMAN SERVICES Highway, Mailstop E–70, Atlanta, GA amozie on DSK3GDR082PROD with NOTICES1 This notice is made in accordance 30341–3717, Telephone: (404) 498– with 35 U.S.C. 209 and 37 CFR part 404. Substance Abuse and Mental Health 2205, Email: cclelland@cdc.gov. The prospective exclusive license will Services Administration SUPPLEMENTARY INFORMATION: Pursuant be royalty bearing, and the prospective Notice of Meetings to Presidential Executive Order 13175 exclusive license may be granted unless signed on November 6, 2000 and the within fifteen (15) days from the date of AGENCY: Substance Abuse and Mental Presidential Memorandum of September this published notice, the National Health Services Administration; Centers 23, 2004, SAMHSA established the VerDate Sep<11>2014 17:08 Jun 27, 2018 Jkt 244001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\28JNN1.SGM 28JNN1


Document Created: 2018-11-06 09:55:13
Document Modified: 2018-11-06 09:55:13
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
FR Citation83 FR 30449 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR